Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

WHO Criteria and Diagnosis in MDS

May 12th 2016

The Broad Spectrum of Myelodysplastic Syndrome

May 12th 2016

FDA Grants Blinatumomab Priority Review for Pediatric Acute Lymphoblastic Leukemia

May 4th 2016

The FDA has granted a priority review to an application to expand the approval of blinatumomab (Blincyto) to include the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Pembrolizumab Granted Breakthrough Designation for Hodgkin Lymphoma

April 18th 2016

The FDA has granted a breakthrough therapy designation to pembrolizumab as a treatment for patients with relapsed or refractory classical Hodgkin lymphoma.

FDA Grants Nivolumab Priority Review in Hodgkin Lymphoma

April 14th 2016

The FDA has granted nivolumab (Opdivo) a priority review for use in previously treated patients with classical Hodgkin lymphoma.

Dr. David Steensma on Myelodysplastic Syndrome

April 11th 2016

David P. Steensma, MD, Senior Physician, Associate Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute discusses myelodysplastic syndromes.

Dr. Cortes on BP-100.01 in Patients With Relapsed/Refractory AML

April 1st 2016

Jorge E. Cortes, MD, deputy department chair, professor of Medicine and Internist, chair, AML Sections, D. B. Lane Cancer Research Distinguished Professor for Leukemia Research, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the mechanism of action for BP-100.01.

EMA Action Brings Nivolumab Closer to First Hematology Approval

March 31st 2016

The European Medicines Agency validated an application for use of nivolumab (Opdivo) for previously treated patients with classical Hodgkin lymphoma), which officially begins the centralized review process for final approval of the drug in the European Union.

Dr. Andre Goy Explains Marginal Zone Lymphoma

March 31st 2016

Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses marginal zone lymphoma.

The Future of Immunotherapy in Myeloma

March 29th 2016

On the Horizon for Multiple Myeloma

March 29th 2016

Antibodies in Combination Therapy for Myeloma

March 29th 2016

Immunotherapy Patient Selection in Myeloma

March 29th 2016

Goals of Therapy in Multiple Myeloma

March 29th 2016

Practical Advice on the Treatment of Multiple Myeloma

March 29th 2016

Safety and Efficacy of Elotuzumab in Multiple Myeloma

March 29th 2016

Safety and Efficacy of Daratumumab in Multiple Myeloma

March 29th 2016

Monoclonal Antibody Therapy in Myeloma

March 29th 2016

Rationale for Immunotherapy in Multiple Myeloma

March 29th 2016

The C Letter Word

March 28th 2016

Hematology/oncology fellowship coordinator, Theresa Marcus, reflects on what it was like to receive a diagnosis of cancer, experience recurrence, and later learn that she had finally become cancer-free with the help of her colleagues.